Skip to content
    QUAD logo

    QUAD

    Seoul, South KoreaFounded 2010
    en.quadim.comLinkedIn
    HealthcareBiotech & Life SciencesData & Analytics

    QUAD Investment Management is an independent, private, discretionary investment management firm based in Seoul, South Korea. Founded in 2010, it manages long-only public equities, hedge funds, venture capital, and private equity funds with a focus on the Korean equity market and healthcare/biotech.

    38% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $36.6M (across 21 rounds with reported amounts).

    Find people at QUAD on Goldilocks AI

    Portfolio

    25

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    1

    Team

    EL

    Eunsil Lee

    Operation

    HB

    Heeku Byun

    Legal & Compliance & Risk Management

    HH

    Hosung Hwang

    CEO

    JY

    Jeongdong Yang

    PI

    JL

    Jihyun Lee

    VC Management

    JJ

    Jonghyuk Jung

    COO, CFO

    MK

    Myungki Kim

    IT

    S(

    Sangkyoon (SK) Han

    CIO

    SP

    Sol Park

    Trading

    YK

    Yonghee Kim

    Administration

    DH

    Dongju Han

    DY

    Dr. Youngtae Hong

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    29 investments
    CompanyRoundAmountDate
    EEnventricIpo—Jun 2026
    Nex-i logoNex-iSeries B—Aug 2025
    Nex-i logoNex-iUnknown—Jan 2025
    HoneyNaps logoHoneyNapsSeries B$11.6MMay 2024
    Vedanta Biosciences logoVedanta BiosciencesSeries D$40MJan 2024
    Avelos Therapeutics logoAvelos TherapeuticsSeries A$8MJan 2024
    Avelos Therapeutics logoAvelos TherapeuticsSeries A$8MAug 2022
    15Five, Inc. logo15Five, Inc.Growth$52MJul 2022
    GFFG logoGFFGSeries A—Jan 2022
    Bisu, Inc. logoBisu, Inc.Seed$3.2MOct 2021
    Bisu logoBisuSeed$3.2MOct 2021
    AAkili, Inc.Series D$110.0MMay 2021
    AAkili, Inc.Series D$110MJan 2021
    Vivi logoViviUnknown$20MJan 2021
    4DMT logo4DMTSeries C$75MJun 2020
    Curiox Biosystems logoCuriox BiosystemsSeries B$15MOct 2019
    The Gardner School logoThe Gardner SchoolUnknown—Oct 2019
    Vedanta Biosciences logoVedanta BiosciencesSeries C$16.6MSep 2019
    Oncorus, Inc logoOncorus, IncSeries B$79.5MJan 2019
    EverEx logoEverExSeries B$10.7MJan 2017
    Pear Therapeutics logoPear TherapeuticsSeries D$80M—
    Ubix Therapeutics logoUbix TherapeuticsIpo$19.5M—
    Mediwhale Inc. logoMediwhale Inc.Series C——
    Kalivir Immunotherapeutics logoKalivir ImmunotherapeuticsSeries A$14M—
    Baram International logoBaram InternationalSeries B——
    Page 1 of 2

    Top Co-Investors

    SV Investment Corporation6 shared
    Korea Investment Partners4 shared
    AJU IB Investment4 shared
    Perceptive Advisors4 shared
    Mirae Asset4 shared
    Industrial Bank of Korea3 shared
    Temasek Holdings (Private) Limited3 shared
    JAZZ Venture Partners3 shared
    Pfizer Ventures3 shared
    Premier Partners3 shared
    IMM Investment3 shared
    SOSV2 shared
    Seventure Partners2 shared
    Revelation Partners2 shared
    AMR Action Fund2 shared
    DSC Investment2 shared
    Atinum Investment2 shared
    Casdin Capital2 shared
    Berkeley Catalyst Fund2 shared
    BVF Partners L.P.2 shared

    Last updated: 20 October 2026